Sector30 Jul 2026Pharming's broader rare-disease story comes into focusWith biotechnology companies, perceptions often lag reality. That is certainly true for Pharming, the Leiden-founded company that is still frequently viewed through the lens of RUCONEST® and milestone-led market updates. Yet the company has evolved.
Sector30 Jul 2026Pharming's broader rare-disease story comes into focusWith biotechnology companies, perceptions often lag reality. That is certainly true for Pharming, the Leiden-founded company that is still frequently viewed through the lens of RUCONEST® and milestone-led market updates. Yet the company has evolved.
Sector30 Jul 2026Pharming's broader rare-disease story comes into focusWith biotechnology companies, perceptions often lag reality. That is certainly true for Pharming, the Leiden-founded company that is still frequently viewed through the lens of RUCONEST® and milestone-led market updates. Yet the company has evolved.
SectorNIZO food research and Winclove Probiotics join forces in strategic partnership built on interdependency and microbial innovation
SectorNIZO food research and Winclove Probiotics join forces in strategic partnership built on interdependency and microbial innovation
SectorNIZO food research and Winclove Probiotics join forces in strategic partnership built on interdependency and microbial innovation
SectorZo pakt Noord-Nederland het groeiende tekort aan mensen en kennis in Life Sciences & Health aan
SectorZo pakt Noord-Nederland het groeiende tekort aan mensen en kennis in Life Sciences & Health aan
SectorZo pakt Noord-Nederland het groeiende tekort aan mensen en kennis in Life Sciences & Health aan
SectorGenmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
SectorGenmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
SectorGenmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
CareerWerken bij MSD in Nederland: waar wetenschap en wereldwijde impact op het gebied van gezondheid samenkomen
CareerWerken bij MSD in Nederland: waar wetenschap en wereldwijde impact op het gebied van gezondheid samenkomen
CareerFrom Bench to Business: What a Week at the BioBusiness Summer School Taught Me About My Own Value
CareerFrom Bench to Business: What a Week at the BioBusiness Summer School Taught Me About My Own Value
CareerWerken bij MSD in Nederland: waar wetenschap en wereldwijde impact op het gebied van gezondheid samenkomen
CareerFrom Bench to Business: What a Week at the BioBusiness Summer School Taught Me About My Own Value
